Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities
Go back to Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities| (NASDAQ: GCTK) | Delayed: 0.64 -0.01 (1.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.65 | 52 Week High | $ | |||
| Open | $0.66 | 52 Week Low | $ | |||
| Day High | $0.67 | P/E | N/A | |||
| Day Low | $0.63 | EPS | $ | |||
| Volume | 74,253 | |||||



